These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29021336)

  • 1. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
    Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
    Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
    BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
    van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
    Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.
    Susantitaphong P; Sewaralthahab K; Balk EM; Eiam-ong S; Madias NE; Jaber BL
    Am J Hypertens; 2013 Mar; 26(3):424-41. PubMed ID: 23382494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
    Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
    J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
    Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
    BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria.
    D'Elia L; Rossi G; Schiano di Cola M; Savino I; Galletti F; Strazzullo P
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1542-52. PubMed ID: 26240299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
    Mahmud HA; Palmer BF
    Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
    Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL; Hirst JA; Taylor KS; Stevens RJ; Roberts NW; Farmer AJ
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.